Journal article
The cardiovascular effects of glucagon‐like peptide‐1 receptor agonists: a trial sequential analysis of randomized controlled trials
Abstract
WHAT IS KNOWN AND OBJECTIVE: Glucagon-like peptide-1 (GLP-1) receptor agonists are a new class of antidiabetic drugs. Their wider use for the treatment of patients with type 2 diabetes mellitus has led to concerns about its cardiovascular effects. However, the robustness of data leading to those concerns is unclear. The purpose of this study is to systematically assess the robustness of the available evidence on the adverse cardiovascular …
Authors
Wu S; Sun F; Zhang Y; Yang Z; Hong T; Chen Y; Zhan S
Journal
Journal of Clinical Pharmacy and Therapeutics, Vol. 39, No. 1, pp. 7–13
Publisher
Hindawi
Publication Date
February 2014
DOI
10.1111/jcpt.12102
ISSN
0269-4727